About Fabhalta® (iptacopan) Fabhalta (iptacopan) is an oral, Factor B inhibitor of the alternative complement pathway 6-7.

CHMP recommends approval of Regeneron's Lynozyfic, Krystal's Vyjuvek, Accord's trabectedin, Takeda's Deqsiga, and 16 label ...

The molecular glue space has attracted several Big Pharma players over the past few years, including Novo Nordisk, Pfizer and ...

Syngenta is continuing to grow its biologicals division with the recent acquisition of certain Novartis technologies.

"Living with kidney disease is a difficult challenge to navigate for patients and their families, and it can feel even more isolating and frustrating when you are living with a rare kidney disease,” ...

Novartis (NYSE:NVS) announced Friday that the European Medicines Agency (EMA), endorsed Fabhalta for the treatment of adults ...

Novartis (NVS) announced that the Committee for Medicinal Products for Human Use, CHMP, of the European Medicines Agency, EMA, has adopted a ...

If approved, Fabhalta® will be the only medicine indicated to selectively target the underlying cause of C3G1, an ultra-rare, progressive kidney disease with no currently approved treatments2-5 Phase ...

Eisai plans to lay off 121 employees in the U.S. A former deputy director of China's drug agency is under investigation by ...

For GSK CEO Emma Walmsley, there was good news and bad news in the company’s annual report. | For GSK CEO Emma Walmsley, ...

Researchers conduct a retrospective, population-based cohort study of adult patients with metastatic breast cancer who underwent genomic profiling at academic institutions.